For years, researchers have known that a diverse group of white blood cells called myeloid-derived suppressor cells (MDSC) are more abundant in cancer patients than in healthy individuals. The cells enhance cancer growth and suppress the specialized T cells that target and destroy tumor cells…
Michigan State University scientists are closer to discovering a possible way to boost healthy cell production in cancer patients as they receive chemotherapy. By adding thymine — a natural building block found in DNA — into normal cells, they found it stimulated gene production and caused them to multiply…
But what happens to these drugs? When do they become accessible to cancer patients — if at all? In a new review published in ecancermedicalscience, researchers trace the journey anti-cancer drugs take between discovery and clinical practice. “Bringing a new medication to clinical practice is a lengthy process and involves many stakeholders with a very diverse background, ranging from researchers, regulatory agencies, payers, physicians and patients,” says Dr Felipe Ades of the Jules Bordet Institute, lead author of the review…